MX2018010508A - Preparaciones mejoradas de celulas progenitoras hepaticas adultas. - Google Patents

Preparaciones mejoradas de celulas progenitoras hepaticas adultas.

Info

Publication number
MX2018010508A
MX2018010508A MX2018010508A MX2018010508A MX2018010508A MX 2018010508 A MX2018010508 A MX 2018010508A MX 2018010508 A MX2018010508 A MX 2018010508A MX 2018010508 A MX2018010508 A MX 2018010508A MX 2018010508 A MX2018010508 A MX 2018010508A
Authority
MX
Mexico
Prior art keywords
progenitor cells
preparations
adult liver
liver progenitor
improved preparations
Prior art date
Application number
MX2018010508A
Other languages
English (en)
Inventor
Sokal Etienne
Lombard Catherine
Dollet Pierre-Edouard
Najimi Mustapha
Original Assignee
Univ Catholique Louvain
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Catholique Louvain filed Critical Univ Catholique Louvain
Publication of MX2018010508A publication Critical patent/MX2018010508A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/407—Liver; Hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/067—Hepatocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5067—Liver cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/14—Coculture with; Conditioned medium produced by hepatocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2531/00—Microcarriers

Abstract

Las preparaciones de células progenitoras hepáticas adultas (denominadas HHALPC) se han fabricado a partir de diferentes donadores humanos y se caracterizan por utilizar marcadores de superficie celular que permitan identificar las preparaciones de las HHALPC y/o los métodos para producirlas que sean los más adecuados para terapia celular, en particular para tratar enfermedades hepáticas o trastornos de coagulación sanguínea hereditarios.
MX2018010508A 2016-03-02 2017-03-02 Preparaciones mejoradas de celulas progenitoras hepaticas adultas. MX2018010508A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16158327 2016-03-02
PCT/EP2017/054859 WO2017149059A1 (en) 2016-03-02 2017-03-02 Improved preparations of adult liver progenitor cells

Publications (1)

Publication Number Publication Date
MX2018010508A true MX2018010508A (es) 2018-11-09

Family

ID=55696855

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010508A MX2018010508A (es) 2016-03-02 2017-03-02 Preparaciones mejoradas de celulas progenitoras hepaticas adultas.

Country Status (14)

Country Link
US (1) US20190046584A1 (es)
EP (1) EP3423566A1 (es)
JP (1) JP2019506890A (es)
KR (1) KR20180114073A (es)
CN (1) CN108779440A (es)
AU (1) AU2017225825A1 (es)
BR (1) BR112018067597A8 (es)
CA (1) CA3013427A1 (es)
EA (1) EA039743B1 (es)
IL (1) IL261383A (es)
MA (1) MA45274A (es)
MX (1) MX2018010508A (es)
SG (1) SG11201807041PA (es)
WO (1) WO2017149059A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6474394B2 (ja) 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
AU2019398753A1 (en) 2018-12-14 2021-08-05 Promethera Therapeutics Sa Cell composition comprising liver progenitor cells expressing HLA-E
TW202035682A (zh) 2018-12-14 2020-10-01 比利時商普羅米修亞生物科技股份有限公司 表現hla-g之肝先驅細胞及取得包含該等細胞之此等細胞組成物之方法與其用途
US20220202874A1 (en) 2019-03-26 2022-06-30 Promethera Therapeutics Sa Adult Liver Progenitor Cells for Treating Non-Alcoholic Fatty Liver Disease
TW202100170A (zh) 2019-03-26 2021-01-01 比利時商普羅米修亞生物科技股份有限公司 用於治療慢性肝衰竭之急性發作的成人肝先驅細胞
CA3137785A1 (en) 2019-04-30 2020-11-05 Promethera Therapeutics Sa Preparation of human allogeneic liver-derived progenitor cells
WO2020221842A1 (en) 2019-04-30 2020-11-05 Promethera Biosciences S.A./N.V. Preparation of human allogeneic liver-derived progenitor cells
TW202128197A (zh) 2019-10-09 2021-08-01 比利時商普羅米修亞生物科技股份有限公司 肝前驅或幹細胞、其溶胞產物、及/或條件培養基於血管高通透性表徵之病症的用途
EP3881853A1 (en) 2020-03-20 2021-09-22 Promethera Therapeutics Sa Human allogeneic liver-derived progenitor cells for use in the treatment of inflammatory and infectious lung diseases and systemic inflammation
CN111778268B (zh) * 2020-06-03 2022-06-21 武汉仝干医疗科技股份有限公司 增强解毒功能基因片段及改造的HepG2细胞
WO2023180122A1 (en) 2022-03-24 2023-09-28 Université Catholique de Louvain Use of human allogenic liver-derived progenitor cells for treating and/or preventing cellular senescence

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006126219A1 (en) 2005-05-26 2006-11-30 Fresenius Medical Care Deutschland G.M.B.H. Liver progenitor cells
ES2359874T5 (es) * 2005-12-21 2014-12-12 Universite Catholique De Louvain Células madre hepáticas aisladas
ES2672205T3 (es) * 2005-12-21 2018-06-13 Université Catholique de Louvain Células madre hepáticas aisladas
JP5822287B2 (ja) * 2008-05-14 2015-11-24 公立大学法人横浜市立大学 ヒト肝幹細胞、その調製方法、分化誘導方法及び利用方法
US8415149B2 (en) * 2010-05-06 2013-04-09 Gwo Xi Stem Cell Applied Technology Co., Ltd. Hepatic progenitor cells and uses thereof
JP6034406B2 (ja) * 2012-01-25 2016-11-30 ユニヴェルシテ カソリック ド ルーヴァンＵｎｉｖｅｒｓｉｔｅ Ｃａｔｈｏｌｉｑｕｅ Ｄｅ Ｌｏｕｖａｉｎ 細胞移植のための組成物および方法
JP6474394B2 (ja) * 2013-07-05 2019-02-27 ユニベルシテ カトリック ドゥ ルーベン ヒト成体肝臓幹細胞由来の馴化培地および肝臓障害の治療におけるその使用
EA034878B1 (ru) * 2013-08-28 2020-04-01 Прометера Байосайенсиз С.А./Н.В. Способ получения клеток-предшественников зрелой печени

Also Published As

Publication number Publication date
AU2017225825A1 (en) 2018-08-16
US20190046584A1 (en) 2019-02-14
EP3423566A1 (en) 2019-01-09
JP2019506890A (ja) 2019-03-14
IL261383A (en) 2018-10-31
BR112018067597A2 (pt) 2019-01-08
KR20180114073A (ko) 2018-10-17
EA039743B1 (ru) 2022-03-05
WO2017149059A1 (en) 2017-09-08
SG11201807041PA (en) 2018-09-27
CN108779440A (zh) 2018-11-09
BR112018067597A8 (pt) 2019-10-15
MA45274A (fr) 2019-01-09
CA3013427A1 (en) 2017-09-08
EA201891913A1 (ru) 2019-02-28

Similar Documents

Publication Publication Date Title
MX2018010508A (es) Preparaciones mejoradas de celulas progenitoras hepaticas adultas.
NZ765695A (en) Immune cell organoid co-cultures
PH12018502429A1 (en) Antibody molecules for cancer treatment
GB2573663A (en) Viral methods of making genetically modified cells
WO2019006418A3 (en) ADENO-ASSOCIATED VIRAL VECTORS FOR GENE THERAPY
MX2022000085A (es) Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad.
MX2020010194A (es) Agente reductor de amoniaco para usarse en el tratamiento de enfermedades asociadas con activacion de celulas estrelladas hepaticas.
MX2017014908A (es) Proteinas de union triespecificas y metodos de uso.
GB2557123A (en) Modified cells and methods of therapy
MX2021006581A (es) Bacterias modificadas para tratar enfermedades asociadas con hiperamonemia.
MX2018001532A (es) Anticuerpos anti-angptl8 y usos de estos.
EA201890725A1 (ru) Агонисты фарнезоидного х-рецептора и их применение
SG10201808053XA (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders
MX2018011035A (es) Anticuerpos-anti-mica.
WO2017136795A8 (en) Bacteria engineered to treat diseases associated with tryptophan metabolism
EP3538119A4 (en) COMPOSITIONS AND METHODS FOR TREATING SKIN DISEASES AND MAINTAINING HEALTHY SKIN
MY196448A (en) Anti-Htra1 Antibodies and Methods of use Thereof
MD3593808T2 (ro) Polimeri de legare a protonilor pentru administrare orală
MX2018014718A (es) Compuestos y su uso para reducir los niveles de ácido úrico.
MX2020000713A (es) Metodos de aferesis y sus usos.
EA201790563A1 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
WO2018138032A3 (en) NKp46 BINDING AGENTS
MX2017005186A (es) Celulas madre neurales estables que comprenden un polinucleótido exógeno que codifica un factor de crecimiento y métodos de uso de las mismas.
EP3784252A4 (en) FUSOGENIC LIPID DNANOPARTICLES AND METHODS FOR THEIR PRODUCTION AND USE IN TARGET CELL SPECIFIC MANUFACTURE OF A THERAPEUTIC PROTEIN AND TREATMENT OF A TARGET CELL RELATED DISEASE, CONDITION OR DISORDER
MX2019005693A (es) Factor viii direccionado a los globulos rojos y metodo para su uso.